Fig. 4From: Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyEstimates of the progression-free survival using Kaplan-Meier analysis (full analysis set, N = 30)Back to article page